CRDL Cardiol Therapeutics Inc

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of July 2024

 

Commission File Number:  001-40712

 

Cardiol Therapeutics Inc.

(Name of registrant)

 

602-2265 Upper Middle Road East

Oakville, Ontario L6H 0G5

Canada

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

x Form 20-F

¨ Form 40-F

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

 

 

INCORPORATION BY REFERENCE

 

Exhibit 99.1 to this report on Form 6-K is hereby incorporated by reference as an Exhibit to the Registration Statement on Form F-10 of Cardiol Therapeutics Inc. (File No. 333-280713), as amended and supplemented.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	CARDIOL THERAPEUTICS INC.
	(Registrant)
Date: July 16, 2024	By:	/s/ Chris Waddick
		Name:	Chris Waddick
		Title:	Chief Financial Officer

 

 

Form 6-K Exhibit Index

 

Exhibit Number		Document Description
99.1		Consent of Borden Ladner Gervais LLP, dated July 16, 2024

 

 

Exhibit 99.1

 

Borden Ladner Gervais LLP Bay Adelaide Centre, East Tower 22 Adelaide Street West Toronto, ON, Canada M5H 4E3 T       416.367.6000 F       416.367.6749 blg.com

 

July 16, 2024

 

Consent of Borden Ladner Gervais LLP

 

We hereby consent to the reference to our name on the face page and under the headings “Documents Filed as Part of the U.S. Registration Statement” and “Legal Matters”, and to the reference to our name and use of our opinions under the headings “Eligibility for Investment” and “Certain Canadian Federal Income Tax Considerations”, in the prospectus supplement dated July 16, 2024 relating to the issuance by Cardiol Therapeutics Inc. of common shares upon exercise of warrants of Cardiol Therapeutics Inc., which forms part of the Registration Statement on Form F-10 (File No. 333- 280713).

 

In giving this consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended.

 

 

/s/ Borden Ladner Gervais LLP
Borden Ladner Gervais LLP

 

 

---